BRAF and cancer: In prognostic terms, CRC patients possessing BRAF exon 15 p.V600E mutations display lower DFS, OS, and cancer-specific survival (CSS) when compared to non-BRAF-mutant CRC regardless of disease stage or chemotherapeutic intervention [94].